Welcome, Guest. Please login or register.
May 20, 2024, 06:36:38 pm

Login with username, password and session length


Members
  • Total Members: 6309
  • Latest: Vicki
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 192
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 168
Total: 168

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: One in Three People Seeking Insurance Coverage for Hep C Drugs Are Denied  (Read 5274 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
A considerable, and rising, proportion of people who apply to their insurance companies for coverage of hepatitis C virus (HCV) medications are flat-out denied.

Publishing their findings in Open Forum Infectious Diseases, researchers conducted a prospective cohort study among 9,025 people from 45 U.S. states who were prescribed a direct-acting antiviral (DAA) regimen for HCV and had a prescription submitted between January 2015 and April 2015 to Diplomat Pharmacy Inc. This company provides hep C pharmacy services across the nation.

Read more...
https://www.hepmag.com/article/one-three-people-seeking-insurance-coverage-hep-c-drugs-denied

Offline dragonslayer

  • Member
  • Posts: 873
There seems to be an important discrepancy in the reports regarding the date range of prescriptions submitted and denied.

In the HEPCMAG article, https://www.hepmag.com/article/one-three-people-seeking-insurance-coverage-hep-c-drugs-denied , it says: 

"Publishing their findings in Open Forum Infectious Diseases, researchers conducted a prospective cohort study among 9,025 people from 45 U.S. states who were prescribed a direct-acting antiviral (DAA) regimen for HCV and had a prescription submitted between January 2015 and April 2015 to Diplomat Pharmacy Inc. This company provides hep C pharmacy services across the nation."

However, in the quoted EurekaAlert press release, https://www.eurekalert.org/pub_releases/2018-06/idso-idf060518.php , it says:

"researchers used data from Diplomat Pharmacy Inc., which provides specialty pharmaceuticals, including direct-acting antiviral drugs for the treatment of hepatitis C, to patients in 45 U.S. states. Their analysis included 9,025 patients who had prescriptions for these drugs submitted to the pharmacy between January 2016 and April 2017."

Clearly, from what weve seen, denials were much higher when these drugs were first  approved for use, and if  January - April 2015 is the correct date of the prescription submissions, we would expect early denials to have been more prevalent than later as it would have represented the initial batch of Harvoni submissions. As we know it took a while for the insurance companies to come around.

But if the 2017 date range is correct, that obviously is much more concerning.
Paul

DX 2008
Started Harvoni 11/26/14 for 8 wks
Completed 8 wks Harvoni 01/20/15
EOT RNA Quant result:  Detected 29
7.5 wk post tx: Detected < LLOQ(12)
11 wk post tx: UNDETECTED SVR12
24 wk post tx: UNDETECTED SVR24; AST 26; ALT 22; ALP 73
48 wk post tx: UNDETECTED SVR48; AST 18; ALT 18; ALP 70
GT 1a
vl 2.4mil
2008 bpx: Stage&Grade 0
2013 bpx: Stage&Grade: 0-1
IL28B: TT
likely infected early '70s

Offline badbradley

  • Member
  • Posts: 294
Browsing through my research I found this

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study

https://jumpshare.com/v/9XI7En9muDeRr5bk0KoS

For DAA prescriptions submitted to a national specialty pharmacy between January 2016 and April 2017, 35.5% were absolutely denied by the insurance carrier.
.....denial  was  higher  among  commercially  insured  (52.4%)  and  Medicaid (34.5%) beneficiaries compared with Medicare beneficiaries (14.7%). Notably, the incidence of denial increased for all insurance types over subsequent quarters during the observation  period.  Finally,  the  incidence  of  absolute  DAA  denial  varied by type of insurance within and across states.
 Contrary  to  our  hypothesis,  the  overall  incidence  of  absolute  denial  in  this  study  (35.5%)  was  substantially  higher  in  magnitude  than  that  observed  in  2  prior  analyses  conducted  shortly  after  the  release  of  all-oral  DAA  regimens  (absolute  denial  range,  8.2%–16.2%)  [17, 18].
     In  prior  studies, denial  of  DAA  therapy  was  reported  to  occur  in  as  high  as  46.3%  of  Medicaid  beneficiaries  [17, 18]. In  contrast,  the  results  of  the  present  study  indicate  that  the  overall  incidence  of  absolute  denial  of  DAAs  is  now  lower  in  magnitude  for  Medicaid  beneficiaries  (34.5%).
      Throughout  the  observation  period,  the  incidence  of  absolute  denial  was  more  common  among  patients  covered  by  commercial  insurance  (52.4%)  than  by  Medicaid  (34.5%,  P  <  .001)  or  Medicare  (14.7%,  P  <  .001).
Geno 1a
Sov/Oly 12wks - relapse
Har/Riba 12wks
Alt-16  Ast-17 SVR - 12
Alt-15  Ast-14 SVR - 24

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.